Sesamol loaded solid lipid nanoparticles: a promising intervention for control of carbon tetrachloride induced hepatotoxicity

Table 2 % inhibition in ALT and AST levels with respect to CCl ₄ group, % increase in ALT and AST levels with respect to VC group and alleviation of the hepatic damage in terms of fold reduction in increased enzyme levels change with respect to CCl ₄

		ALT Levels		AST Levels
Groups	Dose (mg/kg)	% Inhibition versus CCl₄group (% increase with respect to VC)	Alleviation (Fold change with respect to CCl₄)	% Inhibition versus CCl₄group (% increase with respect to VC)	Alleviation (Fold change with respect to CCl₄)
S-SLNs^a	8	52.59 ± 2.37 (1073.93 ± 166.43)	2.12	75.68 ± 3.61 (139.52 ± 51.44)	4.13
FS	8	34.12 ± 3.69 (1677.97 ± 298.08)	1.51	51.84 ± 5.88 (356.79 ± 53.86)	2.09
SILY^a	25	48.84 ± 3.15 (1173.98 ± 166.43)	1.95	75.97 ± 4.04 (129.95 ± 31.47)	4.18
SR	-	19.09 ± 1.38 (1677.97 ± 298.08)	1.23	5.22 ± 2.22 (837.98 ± 148.87)	1.05

Data are expressed as mean ± S.D (n = 6) except for fold change. ^aAll the groups are significantly different from each other at p ≤ 0.001 except for those marked similarly. CCl₄ increased the ALT and AST levels by 2570.07% and 890.89% respectively with respect to VC. Actual values for CCl₄ and VC for ALT are 7.21 ± 0.35 and 0.27 ± 0.05 respectively; AST are 6.50 ± 0.61 and 0.93 ± 0.20 respectively. The actual values are expressed in units of nmoles/nL.

ISSN: 2662-7671